Gerald E. Quirk - 11 Oct 2023 Form 4 Insider Report for Syros Pharmaceuticals, Inc. (SYRS)

Role
Chief Legal & Compliance Offic
Signature
/s/ Todd Rosenthal, as attorney-in-fact
Issuer symbol
SYRS
Transactions as of
11 Oct 2023
Transactions value $
-$14,484
Form type
4
Filing time
20 Oct 2023, 16:23:25 UTC
Previous filing
14 Sep 2023
Next filing
02 Apr 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SYRS Common Stock Options Exercise +22.5K +258.62% 31.2K 11 Oct 2023 Direct F1
transaction SYRS Common Stock Tax liability -$14.5K -6.9K -22.11% $2.10 24.3K 19 Oct 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SYRS Restricted Stock Units Options Exercise $0 -22.5K -50% $0.00 22.5K 11 Oct 2023 Common Stock 22.5K Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares of common stock received upon vesting of a restricted stock unit award.
F2 Represents shares used to cover tax withholding on a restricted stock unit release.
F3 Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.
F4 Represents a restricted stock unit award granted on October 11, 2022. These restricted stock units vested as to one half (50%) of the shares on October 11, 2023, and are scheduled to vest as to one half (50%) of the shares on March 31, 2024.